scholarly journals Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices

2020 ◽  
Author(s):  
Junji Lin ◽  
Lynn McRoy ◽  
Maxine D Fisher ◽  
Nan Hu ◽  
Cralen Davis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Real World ◽  
Medical Records ◽  
Metastatic Breast ◽  
Patient Characteristics ◽  
Treatment Patterns ◽  
Community Oncology ◽  
Label Indication ◽  
Free Rate

Background: Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Materials & methods: Eligible patients receiving palbociclib-based therapy per label indication from 3 February 2015 to 31 December 2017 were included. Descriptive analyses were conducted for patient characteristics, treatment patterns and clinical outcomes. Results: The study included 233 patients who received palbociclib + aromatase inhibitor (P+AI) and 48 who received palbociclib + fulvestrant (P+F). Real-world progression-free rate for P+AI was 69.8% (46.8%) at 12 (24) months (P+F: 43.5% [39.9%]) months. Real-world survival rate was 89.8% (71.4%) at 12 (24) months (P+F: 76.3% [65.0%]). Conclusion: The study findings are consistent with previous studies of palbociclib-based therapy.

Treatment patterns and overall survival in HER2+ metastatic breast cancer at US community oncology practices

2021 ◽  
Author(s):  
Gregory A Vidal ◽  
Santosh Gautam ◽  
Anna Vlahiotis ◽  
Maxine D Fisher ◽  
Sonia Pulgar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Metastatic Breast Cancer ◽  
Real World ◽  
Metastatic Breast ◽  
Standard Of Care ◽  
Treatment Patterns ◽  
Adult Women ◽  
Community Oncology

Aim: To describe real-world treatment patterns/outcomes among patients with HER2+ metastatic breast cancer (MBC). Materials & methods: Real-world treatments and overall survival (OS) were evaluated among adult women diagnosed with HER2+ MBC, with and without brain metastases (BMs), between June 1, 2012 and May 31, 2018 using electronic medical records from the Definitive Oncology Dataset. Results: Among 372 patients, 69% initiated first-line trastuzumab plus pertuzumab-based therapy; many therapy combinations were utilized in the second- to fourth-line. During follow-up (median 24.8 months), 18% of patients died (22% with and 16% without BMs). Mean OS was shortest among patients with BMs at MBC diagnosis in the third- and fourth-line. Conclusion: OS was poor, and no clear standard of care was observed among patients with HER2+ MBC progressing on trastuzumab-based therapies.

Sign in / Sign up

Export Citation Format

Share Document